Researchers from the United Kingdom hope that their findings could pave the way for a urine diagnostic test that could make invasive diagnostic procedures a thing of the past.
The study involved 155 men, 58 of which were diagnosed with prostate cancer, 24 with bladder cancer, and 73 with hematuria, which is characterized by blood leaking into urine. Results from the GC sensor system indicated that through detectable patterns of volatile compounds, urine samples can show the presence of urological cancers.
The GC sensor system, known as Odoreader, was developed by professors Chris Probert of University of Liverpool and Norman Ratcliffe of University of the West of England Bristol, and employed especially developed algorithms in measuring urine samples.
The device features a 30-meter (98-feet) column that allows compounds in the urine to move at various rates, thus producing a sample in a readable format. It then reads the patterns that surface, the prostate gland's proximity to the bladder, for instance, results in a different algorithm if there is cancer present.
With
the phase III CheckMate-141 trial being stopped early due to the
anti–PD-1 agent nivolumab having met its primary endpoint of overall
survival improvement in head and neck cancer, Robert Ferris, MD, PhD,
couldn't be more elated. - See more at:
http://www.targetedonc.com/publications/special-reports/2016/head-and-neck-cancers-issue4/nivolumab-could-change-head-and-neck-cancer-treatment-paradigm#sthash.Fr6wkCLa.dpuf
"To
have an anti–PD-1 agent be proven to improve survival in head and neck
cancer in a randomized phase III trial, and the potential for a new FDA
approval in the near future is a game changer." - See more at:
http://www.targetedonc.com/publications/special-reports/2016/head-and-neck-cancers-issue4/nivolumab-could-change-head-and-neck-cancer-treatment-paradigm#sthash.Fr6wkCLa.dpuf
No comments:
Post a Comment